Your browser doesn't support javascript.
loading
S-Trimer, a COVID-19 subunit vaccine candidate, induces protective immunity in nonhuman primates
Joshua G. Liang; Danmei Su; Tian-Zhang Song; Yilan Zeng; Weijin Huang; Jinhua Wu; Rong Xu; Peiwen Luo; Xiaofang Yang; Xiaodong Zhang; Shuangru Luo; Ying Liang; Xingling Li; Jiaju Huang; Qiang Wang; Xueqin Huang; Qingsong Xu; Mei Luo; Dongxia Luo; Chenyan Zhao; Jian-Bao Han; Yong-Tang Zheng; Peng Liang.
Affiliation
  • Joshua G. Liang; Clover Biopharmaceuticals, Chengdu, China
  • Danmei Su; Clover Biopharmaceuticals, Chengdu, China
  • Tian-Zhang Song; Key Laboratory of Animal Models and Human Disease Mechanisms of the Chinese Academy of Sciences, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunm
  • Yilan Zeng; Public Health Clinical Center of Chengdu, Chengdu, China
  • Weijin Huang; Division of HIV/AIDS and Sex-Transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijin
  • Jinhua Wu; Clover Biopharmaceuticals, Chengdu, China
  • Rong Xu; Clover Biopharmaceuticals, Chengdu, China
  • Peiwen Luo; Clover Biopharmaceuticals, Chengdu, China
  • Xiaofang Yang; Clover Biopharmaceuticals, Chengdu, China
  • Xiaodong Zhang; Clover Biopharmaceuticals, Chengdu, China
  • Shuangru Luo; Clover Biopharmaceuticals, Chengdu, China
  • Ying Liang; Clover Biopharmaceuticals, Chengdu, China
  • Xingling Li; Clover Biopharmaceuticals, Chengdu, China
  • Jiaju Huang; Clover Biopharmaceuticals, Chengdu, China
  • Qiang Wang; Clover Biopharmaceuticals, Chengdu, China
  • Xueqin Huang; Clover Biopharmaceuticals, Chengdu, China
  • Qingsong Xu; Clover Biopharmaceuticals, Chengdu, China
  • Mei Luo; Public Health Clinical Center of Chengdu, Chengdu, China
  • Dongxia Luo; Public Health Clinical Center of Chengdu, Chengdu, China
  • Chenyan Zhao; Division of HIV/AIDS and Sex-Transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijin
  • Jian-Bao Han; Key Laboratory of Animal Models and Human Disease Mechanisms of the Chinese Academy of Sciences, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunm
  • Yong-Tang Zheng; Key Laboratory of Animal Models and Human Disease Mechanisms of the Chinese Academy of Sciences, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunm
  • Peng Liang; Clover Biopharmaceuticals, Chengdu, China
Preprint in En | PREPRINT-BIORXIV | ID: ppbiorxiv-311027
Journal article
A scientific journal published article is available and is probably based on this preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See journal article
ABSTRACT
SARS-CoV-2 is the underlying cause for the COVID-19 pandemic. Like most enveloped RNA viruses, SARS-CoV-2 uses a homotrimeric surface antigen to gain entry into host cells. Here we describe S-Trimer, a native-like trimeric subunit vaccine candidate for COVID-19 based on Trimer-Tag technology. Immunization of S-Trimer with either AS03 (oil-in-water emulsion) or CpG 1018 (TLR9 agonist) plus alum adjuvants induced high-levels of neutralizing antibodies and Th1-biased cellular immune responses in animal models. Moreover, rhesus macaques immunized with adjuvanted S-Trimer were protected from SARS-CoV-2 challenge compared to vehicle controls, based on clinical observations and reduction of viral loads in lungs. Trimer-Tag may be an important new platform technology for scalable production and rapid development of safe and effective subunit vaccines against current and future emerging RNA viruses.
License
cc_no
Full text: 1 Collection: 09-preprints Database: PREPRINT-BIORXIV Type of study: Observational_studies / Prognostic_studies Language: En Year: 2020 Document type: Preprint
Full text: 1 Collection: 09-preprints Database: PREPRINT-BIORXIV Type of study: Observational_studies / Prognostic_studies Language: En Year: 2020 Document type: Preprint